Exelixis
EXEL
$23.36
Share price
2.16%
Change (1 day)
24.28%
Change (1 year)
Categories
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
EPS for Exelixis (EXEL)
EPS in 2023 (TTM): $0.28
According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.28. In 2022 the company made an earnings per share (EPS) of $0.57 a decrease over its 2021 EPS that were of $0.74.
EPS history for Exelixis from 2001 to 2023
Annual EPS
| Year | EPS | Change |
|---|---|---|
| 2023 (TTM) | $0.28 | -50.3% |
| 2022 | $0.57 | -22.97% |
| 2021 | $0.74 | 100% |
| 2020 | $0.37 | -65.09% |
| 2019 | $1.06 | -53.91% |
| 2018 | $2.30 | 333.96% |
| 2017 | $0.53 | -260.61% |
| 2016 | -$0.33 | -58.75% |
| 2015 | -$0.80 | -42.45% |
| 2014 | -$1.39 | 5.3% |
| 2013 | -$1.32 | 43.48% |
| 2012 | -$0.92 | -264.29% |
| 2011 | $0.56 | -165.88% |
| 2010 | -$0.85 | -32.54% |
| 2009 | -$1.26 | -17.65% |
| 2008 | -$1.53 | 75.86% |
| 2007 | -$0.87 | -25.64% |
| 2006 | -$1.17 | 8.33% |
| 2005 | -$1.08 | -42.86% |
| 2004 | -$1.89 | 30.34% |
| 2003 | -$1.45 | -5.23% |
| 2002 | -$1.53 | -0.65% |
| 2001 | -$1.54 |
EPS for similar companies or competitors
| Company | EPS | EPS differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $14.09 | 4,871.87% | 🇺🇸 USA |
 Pfizer PFE | $1.86 | 556.55% | 🇺🇸 USA |
 Amgen AMGN | $14.15 | 4,894.71% | 🇺🇸 USA |
 Sanofi SNY | $3.18 | 1,022.57% | 🇫🇷 France |
 Merck MRK | $1.82 | 543.02% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $3.97 | 1,301.34% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $3.50 | 1,135.69% | 🇬🇧 UK |
 Curis CRIS | -$10.00 | -3,629.83% | 🇺🇸 USA |
 AVEO Oncology
AVEO | -$0.84 | -396.51% | 🇺🇸 USA |